Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Phase Ib Study of Ribociclib Plus Fulvestrant and Ribociclib Plus Fulvestrant Plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast CancerClin. Cancer Res 2020 Oct 12;[EPub Ahead of Print], SM Tolaney, YH Im, E Calvo, YS Lu, E Hamilton, A Forero-Torres, T Bachelot, M Maur, A Fasolo, R Tiedt, L Nardi, U Stammberger, AM Abdelhady, S Ruan, SC Lee
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.